Abstract
BCG is the oldest and most widely used vaccine at presentin the WHO Expanded Programme on Immunization. In a recent meta-analysis, the protective efficacy of BCG in trial was 51% and in the case-control studies 50%. There has been as yet no controlled prospective trial on the efficacy of revaccination. The recent WHO statement does not recommend BCG revaccination. BCG is ne of the vaccines with rare adverse reactions. Lymphadenitis are the most frequent side effects. Disseminated fatal BCG infection is rare. The risk-benefits of a BCG vaccination programme have to be assessed strictly.
